



THC BIOMED INTL LTD.
P.O. Box 20033 Towne Centre
Kelowna, B.C. V1Y 9H2
www.thcbiomed.com

THC ANNOUNCES \$839,974 FINANCING

THC.CSE

THCBF - OTC

TFHC.F

Vancouver, British Columbia – (October 17, 2017) THC BioMed Intl Ltd. (“**THC**” or the “**Company**”) (CSE:THC) announces that it received a total of \$839,974 in advances made on April 20, 2017, May 18, 2017 and June 26, 2017, pursuant to a capital commitment agreement (the “**Agreement**”) dated March 13, 2017, with GEM Global Yield Fund LLC SCS (“**GEM**”). Details of the Agreement were previously announced on March 16, 2017.

The Company issued 1,430,000 units (“**Units**”) to GEM at a price of \$0.5873940559 per unit, for proceeds of \$839,974. Each unit consists of one common share and one common share purchase warrant. Each warrant entitles GEM to purchase one common share of the Company at a price of \$1.20 per share until March 13, 2022. The deemed price of the Units was protected by a price reservation granted by the Canadian Securities Exchange September 18, 2017.

Pursuant to the Agreement, the Company issued an additional 5,205,000 broker warrants to GEM to purchase common shares of THC at a price of \$1.20 per share until March 13, 2022.

Proceeds raised from the investment will be used for working capital and general corporate purposes, particularly to support the activities being generated by THC.

All references to currency are in Canadian dollars.

About THC

THC is a Licensed Producer under Canada’s *ACMPR*. THC’s vision is to be on the leading edge of scientific research, development of products and services related to the medical cannabis industry while creating a standard of excellence. As the industry develops, it will become more important to focus on scientific research and development of products and

services related to medical cannabis. Management believes THC is well-positioned to be in the forefront of this rapidly growing industry.

Please visit our website for a more detailed description of our business and services available.
www.thcbiomed.com

President and CEO:

John Miller

THC Biomed Intl Ltd.

T: 1-844-THCMEDS

E: info@thcbiomed.com

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of THC. Forward-looking information is based on certain key expectations and assumptions made by the management of THC. Although THC believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because THC can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release and include that (a) the proceeds will be used as described, (b) As the industry develops, it will become more important to focus on scientific research and development of products and services related to medical cannabis, and (c) THC will be in the forefront of this rapidly growing industry.

THC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

THE CSE AND ITS REGULATORY SERVICES PROVIDER HAVE NOT REVIEWED AND DO NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE.